View Future GrowthCurasight 과거 순이익 실적과거 기준 점검 0/6Curasight의 수입은 연평균 -38.4%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 13.3% 증가했습니다.핵심 정보-38.37%순이익 성장률-22.88%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률n/a자기자본이익률-919.25%순이익률n/a다음 순이익 업데이트27 Aug 2026최근 과거 실적 업데이트공시 • Feb 24+ 3 more updatesCurasight A/S to Report Q4, 2025 Results on Feb 26, 2026Curasight A/S announced that they will report Q4, 2025 results on Feb 26, 2026공시 • Jan 28Curasight A/S to Report Fiscal Year 2025 Results on Feb 26, 2026Curasight A/S announced that they will report fiscal year 2025 results on Feb 26, 2026공시 • Feb 27Curasight A/S to Report Fiscal Year 2024 Final Results on Mar 26, 2025Curasight A/S announced that they will report fiscal year 2024 final results on Mar 26, 2025공시 • Feb 05+ 2 more updatesCurasight A/S to Report First Half, 2025 Results on Aug 28, 2025Curasight A/S announced that they will report first half, 2025 results on Aug 28, 2025공시 • Jan 22Curasight A/S to Report Fiscal Year 2024 Results on Feb 20, 2025Curasight A/S announced that they will report fiscal year 2024 results on Feb 20, 2025모든 업데이트 보기Recent updates공시 • Jun 09Curasight Announces Preliminary Readout from Phase 1 Clinical Trial with uTREAT In Aggressive Brain CancerCurasight A/S announced encouraging preliminary readout from its Phase 1 clinical trial with uTREAT in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the Phase 1 clinical trial with uTREAT in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support: The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using mannitol. High uptake and retention in tumor. Biodistribution and dosimetry compatible with the ability to deliver a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs. The data support continued development of Curasight's therapeutic program using uTREAT in aggressive brain cancer. The trial aims to investigate Curasight's uTREAT as a new targeted radioligand therapy for patients with glioblastoma. Participants in the trial are patients with newly diagnosed, verified or suspected GBM. uTREAT is administered via a catheter directly into the vessels that feed the tumor (super SIACI). To enhance tumor targeting, the blood-brain barrier is transiently opened with the osmotic compound mannitol. The mode of administration is designed to achieve high binding of uTREAT in tumors while minimizing radiation exposure to healthy organs. Curasight's uPAR theranostic platform combines two key technologies - uTRACE and uTREAT - both targeting uPAR. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical therapy solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight's ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately 50% of patients die within 14 months, and after five years from diagnosis, only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially complement current radiation strategies and reduce radiation exposure to healthy brain tissue due to more specific tumor tissue targeting.Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Colin Hayward was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Mar 25Curasight A/S Announces Board ChangesCurasight A/S announced that Marcel Reichen and Colin Hayward as new board members replacing Lars Trolle and Charlotte Vedel with consent of all votes represented at the general meeting. Andreas Kjær was elected as deputy chairman of the Board of Directors.공시 • Feb 24+ 3 more updatesCurasight A/S to Report Q4, 2025 Results on Feb 26, 2026Curasight A/S announced that they will report Q4, 2025 results on Feb 26, 2026공시 • Jan 28Curasight A/S to Report Fiscal Year 2025 Results on Feb 26, 2026Curasight A/S announced that they will report fiscal year 2025 results on Feb 26, 2026공시 • Jan 13Curasight A/S Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-In-Class Radiopharmaceutical Utreat in High-Grade GliomasCurasight A/S announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas. Position emission tomography (PET)- images from the first treated patient showed clear and sustained uptake of uTREAT in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient's PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT has protracted binding kinetics, translating to a maximized tumor absorbed dose. These early results provide support for Curasight's uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT as a novel therapy for patients with high- grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors). The preliminary dosimetry readout of uTREAT was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in second quarter of 2026. The phase 1 clinical trial is designed to evaluate the dosimetry and safety of Curasight's drug candidate uTREAT as a first-in-class uPAR targeted radiopharmaceutical therapy in patients with newly diagnosed, verified or suspected glioblastoma (GBM). Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from research and earlier studies with uTRACE as well as protocol discussions with Key Opinion Leaders. Curasight's uPAR theranostic platform combines two key technologies - uTRACE (highly precise PET imaging diagnostic) and uTREAT (highly precise radiopharmaceutical therapy) both targeting uPAR (urokinase-type plasminogen activator receptor) with the same uPAR binding peptide AE105. Together, they form an integrated approach to next generation radiopharmaceuticals in aggressive solid tumors. uTRACE is fully developed, GMP manufactured and validated in 9 clinical trials (450 patients). uTRACE is partnered with Curium Inc. in the field of diagnostics for prostate cancer. Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children.공시 • Dec 19Curasight A/S Announces Successful Dosing of First Patient in Phase 1 Trial with Utreat®? in Brain CancerCurasight A/S announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the initiation of the first clinical trial under the company's therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma. The start of the phase 1 study with uTREAT means that Curasight is now in the clinical phase with both parts of its theranostic platform aimed at improving treatment and diagnosis of certain cancers. The company's diagnostic platform uTRACE is currently in a Phase 2 trial for prostate cancer under the strategic partnership with Curium Inc. The trial aims to investigate Curasight's uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with Key Opinion Leaders.공시 • Feb 27Curasight A/S to Report Fiscal Year 2024 Final Results on Mar 26, 2025Curasight A/S announced that they will report fiscal year 2024 final results on Mar 26, 2025공시 • Feb 05+ 2 more updatesCurasight A/S to Report First Half, 2025 Results on Aug 28, 2025Curasight A/S announced that they will report first half, 2025 results on Aug 28, 2025공시 • Jan 22Curasight A/S to Report Fiscal Year 2024 Results on Feb 20, 2025Curasight A/S announced that they will report fiscal year 2024 results on Feb 20, 2025매출 및 비용 세부 내역Curasight가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:CUS 매출, 비용 및 순이익 (DKK Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-636031 Dec 250-535030 Sep 250-485030 Jun 250-436031 Mar 250-346031 Dec 240-377030 Sep 240-327030 Jun 240-327031 Mar 240-297031 Dec 230-266030 Sep 230-274030 Jun 230-255031 Mar 230-195031 Dec 220-185030 Sep 220-155030 Jun 220-133031 Mar 220-112031 Dec 210-81030 Sep 210-71030 Jun 210-71031 Mar 210-61031 Dec 200-61031 Dec 190-110양질의 수익: CUS 은(는) 현재 수익성이 없습니다.이익 마진 증가: CUS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CUS은 수익성이 없으며 지난 5년 동안 손실이 연평균 38.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CUS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CUS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CUS는 현재 수익성이 없으므로 자본 수익률이 음수(-919.25%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 16:08종가2026/07/06 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Curasight A/S는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Feb 24+ 3 more updatesCurasight A/S to Report Q4, 2025 Results on Feb 26, 2026Curasight A/S announced that they will report Q4, 2025 results on Feb 26, 2026
공시 • Jan 28Curasight A/S to Report Fiscal Year 2025 Results on Feb 26, 2026Curasight A/S announced that they will report fiscal year 2025 results on Feb 26, 2026
공시 • Feb 27Curasight A/S to Report Fiscal Year 2024 Final Results on Mar 26, 2025Curasight A/S announced that they will report fiscal year 2024 final results on Mar 26, 2025
공시 • Feb 05+ 2 more updatesCurasight A/S to Report First Half, 2025 Results on Aug 28, 2025Curasight A/S announced that they will report first half, 2025 results on Aug 28, 2025
공시 • Jan 22Curasight A/S to Report Fiscal Year 2024 Results on Feb 20, 2025Curasight A/S announced that they will report fiscal year 2024 results on Feb 20, 2025
공시 • Jun 09Curasight Announces Preliminary Readout from Phase 1 Clinical Trial with uTREAT In Aggressive Brain CancerCurasight A/S announced encouraging preliminary readout from its Phase 1 clinical trial with uTREAT in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the Phase 1 clinical trial with uTREAT in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support: The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using mannitol. High uptake and retention in tumor. Biodistribution and dosimetry compatible with the ability to deliver a therapeutically relevant radiation dose to the tumor without reaching dose limits for healthy organs. The data support continued development of Curasight's therapeutic program using uTREAT in aggressive brain cancer. The trial aims to investigate Curasight's uTREAT as a new targeted radioligand therapy for patients with glioblastoma. Participants in the trial are patients with newly diagnosed, verified or suspected GBM. uTREAT is administered via a catheter directly into the vessels that feed the tumor (super SIACI). To enhance tumor targeting, the blood-brain barrier is transiently opened with the osmotic compound mannitol. The mode of administration is designed to achieve high binding of uTREAT in tumors while minimizing radiation exposure to healthy organs. Curasight's uPAR theranostic platform combines two key technologies - uTRACE and uTREAT - both targeting uPAR. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical therapy solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight's ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers. Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately 50% of patients die within 14 months, and after five years from diagnosis, only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT could potentially complement current radiation strategies and reduce radiation exposure to healthy brain tissue due to more specific tumor tissue targeting.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Colin Hayward was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Mar 25Curasight A/S Announces Board ChangesCurasight A/S announced that Marcel Reichen and Colin Hayward as new board members replacing Lars Trolle and Charlotte Vedel with consent of all votes represented at the general meeting. Andreas Kjær was elected as deputy chairman of the Board of Directors.
공시 • Feb 24+ 3 more updatesCurasight A/S to Report Q4, 2025 Results on Feb 26, 2026Curasight A/S announced that they will report Q4, 2025 results on Feb 26, 2026
공시 • Jan 28Curasight A/S to Report Fiscal Year 2025 Results on Feb 26, 2026Curasight A/S announced that they will report fiscal year 2025 results on Feb 26, 2026
공시 • Jan 13Curasight A/S Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-In-Class Radiopharmaceutical Utreat in High-Grade GliomasCurasight A/S announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas. Position emission tomography (PET)- images from the first treated patient showed clear and sustained uptake of uTREAT in the tumor, confirming that the drug successfully targets cancer tissue. The signal remained visible for at least 24 hours, indicating prolonged tumor binding and supporting the potential for effective radiation delivery to the tumor. The patient's PET signal persisted until the last PET scan (24 hours), demonstrating that uTREAT has protracted binding kinetics, translating to a maximized tumor absorbed dose. These early results provide support for Curasight's uPAR-targeted approach in radiopharmaceuticals and the potential of uTREAT as a novel therapy for patients with high- grade gliomas and other uPAR expressing aggressive solid tumors (>85% of solid tumors). The preliminary dosimetry readout of uTREAT was in line with expectations and supports to continue with additional GBM patients. Currently more patients are enrolled, and top-line data is expected in second quarter of 2026. The phase 1 clinical trial is designed to evaluate the dosimetry and safety of Curasight's drug candidate uTREAT as a first-in-class uPAR targeted radiopharmaceutical therapy in patients with newly diagnosed, verified or suspected glioblastoma (GBM). Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from research and earlier studies with uTRACE as well as protocol discussions with Key Opinion Leaders. Curasight's uPAR theranostic platform combines two key technologies - uTRACE (highly precise PET imaging diagnostic) and uTREAT (highly precise radiopharmaceutical therapy) both targeting uPAR (urokinase-type plasminogen activator receptor) with the same uPAR binding peptide AE105. Together, they form an integrated approach to next generation radiopharmaceuticals in aggressive solid tumors. uTRACE is fully developed, GMP manufactured and validated in 9 clinical trials (450 patients). uTRACE is partnered with Curium Inc. in the field of diagnostics for prostate cancer. Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10 % of the patients are children.
공시 • Dec 19Curasight A/S Announces Successful Dosing of First Patient in Phase 1 Trial with Utreat®? in Brain CancerCurasight A/S announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the initiation of the first clinical trial under the company's therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma. The start of the phase 1 study with uTREAT means that Curasight is now in the clinical phase with both parts of its theranostic platform aimed at improving treatment and diagnosis of certain cancers. The company's diagnostic platform uTRACE is currently in a Phase 2 trial for prostate cancer under the strategic partnership with Curium Inc. The trial aims to investigate Curasight's uTREAT as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. Participants in the trial are patients with newly diagnosed verified or suspected GBM. The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with Key Opinion Leaders.
공시 • Feb 27Curasight A/S to Report Fiscal Year 2024 Final Results on Mar 26, 2025Curasight A/S announced that they will report fiscal year 2024 final results on Mar 26, 2025
공시 • Feb 05+ 2 more updatesCurasight A/S to Report First Half, 2025 Results on Aug 28, 2025Curasight A/S announced that they will report first half, 2025 results on Aug 28, 2025
공시 • Jan 22Curasight A/S to Report Fiscal Year 2024 Results on Feb 20, 2025Curasight A/S announced that they will report fiscal year 2024 results on Feb 20, 2025